Published in Nat Rev Genet on January 01, 2009
Genetic testing and common disorders in a public health framework: how to assess relevance and possibilities. Background Document to the ESHG recommendations on genetic testing and common disorders. Eur J Hum Genet (2011) 1.57
Legislation on direct-to-consumer genetic testing in seven European countries. Eur J Hum Genet (2012) 1.53
Incidental findings of uncertain significance: To know or not to know - that is not the question. BMC Med Ethics (2016) 1.39
Where are you going, where have you been: a recent history of the direct-to-consumer genetic testing market. J Community Genet (2010) 1.28
Users' motivations to purchase direct-to-consumer genome-wide testing: an exploratory study of personal stories. J Community Genet (2011) 1.28
Is there a doctor in the house? : The presence of physicians in the direct-to-consumer genetic testing context. J Community Genet (2011) 1.25
Parents' attitudes toward pediatric genetic testing for common disease risk. Pediatrics (2011) 1.18
Health-related direct-to-consumer genetic testing: a review of companies' policies with regard to genetic testing in minors. Fam Cancer (2009) 1.18
Are the kids really all right? Direct-to-consumer genetic testing in children: are company policies clashing with professional norms? Eur J Hum Genet (2011) 0.98
Ethical issues of predictive genetic testing for diabetes. J Diabetes Sci Technol (2009) 0.89
Current issues in medically assisted reproduction and genetics in Europe: research, clinical practice, ethics, legal issues and policy. European Society of Human Genetics and European Society of Human Reproduction and Embryology. Eur J Hum Genet (2013) 0.87
New era for personalized medicine: the diagnosis and management of age-related macular degeneration. Clin Experiment Ophthalmol (2009) 0.83
Ethical considerations for pharmacogenomic testing in pediatric clinical care and research. Pharmacogenomics (2011) 0.81
Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation. J Obstet Gynaecol Can (2007) 2.09
Whole-genome sequencing in health care: recommendations of the European Society of Human Genetics. Eur J Hum Genet (2013) 1.93
Citizens' values regarding research with stored samples from newborn screening in Canada. Pediatrics (2012) 1.48
Legal approaches regarding health-care decisions involving minors: implications for next-generation sequencing. Eur J Hum Genet (2017) 1.39
Whole-genome sequencing in newborn screening programs. Sci Transl Med (2014) 1.34
Preconceptional genetic carrier testing and the commercial offer directly-to-consumers. Hum Reprod (2011) 1.32
Whole-genome sequencing in health care. Recommendations of the European Society of Human Genetics. Eur J Hum Genet (2013) 1.31
Reconsidering reproductive benefit through newborn screening: a systematic review of guidelines on preconception, prenatal and newborn screening. Eur J Hum Genet (2010) 1.29
Where are you going, where have you been: a recent history of the direct-to-consumer genetic testing market. J Community Genet (2010) 1.28
Users' motivations to purchase direct-to-consumer genome-wide testing: an exploratory study of personal stories. J Community Genet (2011) 1.28
The expansion of newborn screening: is reproductive benefit an appropriate pursuit? Nat Rev Genet (2009) 1.21
Health-related direct-to-consumer genetic testing: a review of companies' policies with regard to genetic testing in minors. Fam Cancer (2009) 1.18
Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer. J Med Genet (2006) 1.17
Storing newborn blood spots: modern controversies. J Law Med Ethics (2004) 1.14
Pediatric research and the return of individual research results. J Law Med Ethics (2011) 1.14
Science and society: children and incompetent adults in genetic research: consent and safeguards. Nat Rev Genet (2002) 1.13
Hereditary motor and sensory neuropathy with agenesis of the corpus callosum. Ann Neurol (2003) 1.05
Cohort profile: the maternal-infant research on environmental chemicals research platform. Paediatr Perinat Epidemiol (2013) 1.03
Factors influencing intrafamilial communication of hereditary breast and ovarian cancer genetic information. Eur J Hum Genet (2009) 0.99
Are the kids really all right? Direct-to-consumer genetic testing in children: are company policies clashing with professional norms? Eur J Hum Genet (2011) 0.98
Personalized medicine and access to health care: potential for inequitable access? Eur J Hum Genet (2012) 0.92
Attitudes of Canadian researchers toward the return to participants of incidental and targeted genomic findings obtained in a pediatric research setting. Genet Med (2013) 0.91
"I prefer a child with …": designer babies, another controversial patent in the arena of direct-to-consumer genomics. Genet Med (2013) 0.90
A review of the barriers to sharing in biobanking. Biopreserv Biobank (2013) 0.90
Paediatric biobanks: what makes them so unique? J Paediatr Child Health (2011) 0.87
Recruiting terminally ill patients into non-therapeutic oncology studies: views of health professionals. BMC Med Ethics (2012) 0.87
Guidance for considering ethical, legal, and social issues in health technology assessment: application to genetic screening. Int J Technol Assess Health Care (2008) 0.86
Expectations and values about expanded newborn screening: a public engagement study. Health Expect (2013) 0.86
Physicians and genetic malpractice. Med Law (2002) 0.83
Emerging issues in paediatric health research consent forms in Canada: working towards best practices. BMC Med Ethics (2013) 0.83
Newborn blood spot screening in four countries: stakeholder involvement. J Public Health Policy (2008) 0.82
Exploring resources for intrafamilial communication of cancer genetic risk: we still need to talk. Eur J Hum Genet (2013) 0.82
Non-invasive prenatal testing for aneuploidy and beyond: challenges of responsible innovation in prenatal screening. Eur J Hum Genet (2015) 0.80
Vaccines of the 21st century and vaccinomics: data-enabled science meets global health to spark collective action for vaccine innovation. OMICS (2011) 0.80
Understanding umbilical cord blood banking: what women need to know before deciding. Womens Health Issues (2007) 0.80
Forward Look: Tenth Anniversary of the Human Genome Sequence and 21 Century Postgenomics Global Health - A Close Up on Africa and Women's Health. Curr Pharmacogenomics Person Med (2011) 0.79
Direct-to-consumer genetic testing: driving choice? Expert Rev Mol Diagn (2010) 0.79
Intrafamilial disclosure of risk for hereditary breast and ovarian cancer: points to consider. J Community Genet (2012) 0.79
Pharmacogenetics of opioids for the treatment of acute maternal pain during pregnancy and lactation. Curr Drug Metab (2012) 0.79
An ethical and legal overview of pharmacogenomics: perspectives and issues. Med Law (2008) 0.78
The communication of pharmacogenetic research results: participants weigh in on their informational needs in a pilot study. J Popul Ther Clin Pharmacol (2011) 0.78
Physician recruitment of patients to non-therapeutic oncology clinical trials: ethics revisited. Front Pharmacol (2013) 0.77
[Severe neuropathy with agenesis of the corpus callosum]. Med Sci (Paris) (2003) 0.77
Public concerns regarding the storage and secondary uses of residual newborn bloodspots: an analysis of print media, legal cases, and public engagement activities. J Community Genet (2014) 0.76
Genetic testing: anonymity of sperm donors under threat. Nature (2013) 0.75
Are we asking the right ethics questions on drug shortages? Suggestions for a global and anticipatory ethics framework. Am J Bioeth (2012) 0.75
Ethics, industry and 'animal farm'. Nat Biotechnol (2004) 0.75
Responsible implementation of expanded carrier screening. Eur J Hum Genet (2017) 0.75